Platelet Rich Plasma for Uterine Scar

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-52
SponsorThe University of Texas Health Science Center, Houston

About this trial

When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.

Eligibility criteria

Qualifiers

Women undergoing elective cesarean delivery

Term pregnancy (≥37 weeks of gestation)

Disqualifiers

Thrombocytopenia (CBC Platelet count <70,000)

Connective tissue disease

Uterine scars other than cesarean (s/p myomectomy, s/p cornual resection)

Malformed uterus (unicornuate, bicornuate, didelphic)

Trial design

Treatments tested in this trial

  • Platelet Rich Plasma
  • Placebo

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators